Aurora Biolabs, a recognized leader in RAS-targeted protein production, assay development, and co-crystal structure determination, has announced the launch of the industry’s first binding assay for screening KRAS G12D/Cyclophilin A (CypA)/inhibitor tri-complexes. This milestone represents a significant leap in accelerating drug discovery for one of the most critical oncogenic targets in cancer biology.
Affinity tags are highly effective tools used for the expression and purification of recombinant proteins. However...
SARS-CoV-2, the viral agent responsible for the COVID-19 pandemic, is composed of an assortment of gene products critical to the viral lifecycle.
The KRAS gene plays important roles in cell division, cell differentiation, and apoptosis. We offer an assortment of KRAS recombinant protein...
Aurora Biolabs, Inc. (ABL) is excited to announce that we are starting to offer highly purified eIF4E proteins for research and drug discovery.
Dr. Ronald M. Evans’ group found a new role of human FGF1 in type 2 diabetes. In mice with diet-induced diabetes...
